Abbott Laboratories ABT reported first-quarter 2025 adjusted earnings per share (EPS) of $1.09, which beat the Zacks ...

Analysts are estimating that Abbott Laboratories will report an earnings per share (EPS) of $1.07. The market awaits Abbott ...

Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.82, a high estimate of $160.00, and a low estimate of $135.00. This upward trend is apparent, with the ...

Abbott announced the launch of its neuromodulation business’ next-generation delivery system, which will be used to streamline the implantation process for electrodes used as part of its Proclaim DRG ...

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to ...

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

Nexalin has received patent approval from the USPTO for its DIFS method for treating substance use disorders (SUD).